HPV16 L1 Antibody (Conformational Antibody), Mouse MAb

RRID Number: AB_2860538
Price:
Size:
Number:

HPV16 L1 Antibody (Conformational Antibody), Mouse MAb General Information

Product name
HPV16 L1 Antibody (Conformational Antibody), Mouse MAb
Validated applications
ELISA
Application notes
IHC, FCM, IF, IP et al. applications haven't been validated. (Antibody's applications haven't been validated with corresponding virus positive samples. Optimal concentrations/dilutions should be determined by the end user.)
Specificity
HPV HPV capsid L1
Immunogen
Recombinant HPV16 L1 virus like particle
Preparation
This antibody was produced from a hybridoma resulting from the fusion of a mouse myeloma with B cells obtained from a mouse immunized with purified, recombinant HPV16 L1 virus like particle. The IgG fraction of the cell culture supernatant was purified by Protein A affinity chromatography.
Source
Monoclonal Mouse IgG1 Clone #01
Purification
Protein A
Formulation
0.2 μm filtered solution in PBS
Conjugate
Unconjugated
Form
Liquid
Shipping
This antibody is shipped as liquid solution at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Storage
This antibody can be stored at 2℃-8℃ for one month without detectable loss of activity. Antibody products are stable for twelve months from date of receipt when stored at -20℃ to -80℃. Preservative-Free. Avoid repeated freeze-thaw cycles.

HPV16 L1 Antibody (Conformational Antibody), Mouse MAb Validated Applications

Application Dilution
ELISA 1:1000-1:2000
Please Note: Optimal concentrations/dilutions should be determined by the end user.

HPV capsid L1 Background Information

Papillomaviruses are highly species-specific and can cause squamous epithelial and fibroepithelial tumors in their hosts. Human papillomaviruses (HPVs) are associated with benign and malignant hyperproliferation of cells, with a wide variety of clinical manifestations ranging from condyloma acuminata to cervical carcinoma. HPV infection is the most common sexually transmitted disease. More than 4 HPV types so far identified are known to infect the genital tract. Genital HPVs are divided into `low risk' HPVs such as HPV 6 and 11 and ‘high risk’ HPV types such as 16, 18, 31, 33, 35, 39, 45 and 52, 58 which are responsible for more than 95% of HPV-induced cervical cancer. Vaccination against these high risk types seems to be the most feasible prevention for cervical cancer. Indeed, clinical trials have shown prophylactic HPV vaccines to be effective against HPV infection, cervical intraepithelial neoplasia (CIN), and genital warts, but protection is type-specific and the currently developed vaccines target only a few types. These vaccines are based on papillomavirus-like particles (VLPs) composed of the major capsid protein, L1. The L1 protein self assembles into VLPs when expressed at high levels in eukaryotic or insect cells. VLPs are composed of 36 copies of L1 protein organized into 72 pentamers, so called capsomeres, to form particles which are immunologically indistinguishable from native virions. Experimentally induced VLP antisera have been shown to be mostly typespecific with respect to neutralization. Minor cross-neutralization has been observed only between closely related HPV types, e.g. HPV6 and 11, HPV18 and 45, or HPV16 and 31. Structure analysis has revealed the presence of several hyper variable loops on the outer surface of the capsid. With a few exceptions, all HPV-neutralizing monoclonal antibodies analyzed so far are type-specific and recognize conformational epitopes within surface-exposed hyper variable loops of the major capsid protein L1.
References
  • Zur Hausen, H., 1989, Cancer Res. 49: 4677-4691.
  • Chan, SY, et al., 1995, J. Virol. 69: 3074-3083.
  • Lorincz AT, et al., 1992, Obstet Gynecol. 79: 328-337.
  • Munoz N, et al., 2003, N Engl J Med. 348: 518-527.
  • Pastrana DV, et al., 2004, Virology. 321: 205-216.
  • Christensen ND, et al., 1996, Virology. 224: 477-486.
  • Combita AL, et al., 2002, J Virol. 76: 6480-6486.
  • Christensen ND, et al., 2001, Virology. 291:324-334.
  • Fleury MJ, et al., Arch Virol. 2006, 151: 1511-1523.

Standard Antibody Development Service

Rabbit MAb

Mouse MAb

Rabbit PAb

Fast Antibody Development Service

Mouse MAb

Rabbit PAb

Add to Cart Successfully Add to Cart Failed Shopping cart is being updated, please wait U.S.A.